for people ages 18 years and up (full criteria)
at UC Irvine UCSD
study started
estimated completion
Principal Investigator
by Lauren C. Pinter-Brown, MD (uci)Ayad Hamdan, M.D. (ucsd)
Headshot of Ayad Hamdan
Ayad Hamdan



AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells. This clinical trial is conducted in two phases. The primary objective of Phase 1 is to test the safety of AB-101 given alone or in combination with rituximab. The primary objective of Phase 2 is to determine if AB-101 in combination with rituximab has activity in patients with relapsed/refractory Non-Hodgkin lymphoma of B-cell origin. Patients will receive eight weekly doses of AB-101 followed by scheduled assessments of overall health and tumor response.

Official Title

A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin


Non Hodgkin Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Cyclophosphamide, Rituximab, Fludarabine, Interleukin-2


You can join if…

Open to people ages 18 years and up

  • Confirmed diagnosis of indolent or aggressive NHL of B-cell origin
  • Patient must have progressed or demonstrated intolerance to at least two lines of FDA-approved therapies, one of which must have included anti-CD20 monoclonal antibody therapy. Prior hematopoietic stem cell transplantation or treatment with FDA-approved CAR-T therapy is permitted.
  • Patient must have disease that allows for response assessment using the Lugano Classification criteria.
  • For Group 2 patients, confirmed CD20-positive disease

You CAN'T join if...

  • Active CNS lymphoma or CNS involvement
  • Cardiac impairment with symptoms of New York Heart Association Classification of III or IV
  • Cardiac ejection fraction of < 45% on echocardiogram or MUGA scan at screening assessment
  • Inadequate pulmonary function
  • History of a solid organ allograft, or an inflammatory or autoimmune disease likely to be exacerbated by IL-2
  • Ongoing uncontrolled systemic infections


  • University of California, Irvine accepting new patients
    Orange California 92868 United States
  • University of California San Diego Moores Cancer Center accepting new patients
    San Diego California 92093 United States

Lead Scientists at University of California Health


accepting new patients
Start Date
Completion Date
Artiva Biotherapeutics, Inc.
Phase 1/2 research study
Study Type
Expecting 60 study participants
Last Updated